Very useful. First time I've seen this. Thanks Cabel.

The evidence for an increase in eGFR in patients given ABL compared with placebo is not strong. A clinical trials statistician would want to see a significant difference between the changes in eGFR in the two groups. They must have looked at this, but as they did not mention the result, it's safe to assume it was not significant.

One would also expect a clinically meaningful increase in eGFR to be accompanied by a decrease in blood urea compared with placebo, which did not seem to happen. 

The ALP data are stronger because there was a sig diff between the groups in the changes during treatment. But the numbers are small, of course. 

An increase in eGFR in BETonMACE remains possible, but that's as far as it goes imo. Let's hope we get some info soon.